During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty will discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC. In addition, they will address how to integrate next generation sequencing (NGS) into your biomarker testing workflows and optimize its use for patients. Finally, they will share best practices in biomarker testing, reporting, and communication to help pathologists and laboratory professionals guide medical oncologists and other team members in the appropriate diagnosis, testing, and treatment for patients.
The activity offers 1.0 CME/CMLE credit.
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Learning Objectives
Upon completion of this activity, you should be able to:
· Describe ongoing investigational efforts regarding emerging biomarkers in metastatic NSCLC
· Utilize NGS to identify current and emerging biomarkers to predict response to personalized therapies for patients with metastatic NSCLC
· Employ strategies for optimizing workflows and turnaround times for NGS
· Discuss the science behind resistance mechanisms in patients with metastatic NSCLC
· Recognize the use of emerging I-O combination therapies and potential biomarkers in patients with metastatic NSCLC
· Develop ways to improve communication among pathologists, oncologists, and other members of the multidisciplinary lung cancer care team
Faculty
Diana N. Ionescu MD, FRCPC, FCAP
Consultant Pathologist and Medical Lead Anatomical Pathology
Medical Director BC Cervical Cancer Screening Laboratory
Medical Director Clinical Trials, BC Cancer Laboratories
Clinical Professor of Pathology, University of British Columbia
Doru Paul, MD, PhD
Attending Physician, Division of Hematology and Medical Oncology
Weill Cornell and New York Presbyterian Hospital
Faculty Disclosures
The following Panel/Faculty members have relevant financial relationships to disclose:
| Faculty Member | Ineligible Company | For what role?
| Diana Ionescu, MD | AstraZeneca, Bayer, BMS, Merck, Pfizer, Roche | Consultant, Consultant, Consultant, Consultant, Consultant, Consultant
Dr. Paul has no relevant financial relationships to disclose
All of the relevant financial relationships listed for these individuals have been mitigated
Commercial Support
Funded by an independent educational grant from AstraZeneca Pharmaceuticals
Women Trailblazers in a Multigenerational Workplace
Special Episode: Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
Special Episode: CRC Biomarkers and the Impact on Patients’ Lives
Special Episode: Emerging Biomarkers for the Assessment of Alzheimer's Disease
Special Episode:How Advances in Treatment for NSCLC and Melanoma Impact the Laboratory
S4Ep2: The FDA’s Proposed Rule on Laboratory Developed Tests
S4Ep1: Patient-Centered Care from a Laboratory Perspective
S3Ep15: Strategies for Promoting DEI in the Lab
S3Ep14: Mentorship in the Medical Laboratory
S3Ep13: A Storied Career in Gynecologic Pathology—featuring Dr. Elvio Silva
S3Ep12: Transitioning to Leadership Outside the Laboratory
S3Ep11: 10 Lab Safety Issues That Put You at Risk
S3EP10: Saved by the Lab: A LIVE ‘90s Trivia Contest
S3Ep9-Sometimes It’s a Zebra: Unusual Cases in the Microbiology Lab
S3Ep8: Amplifying the Voice of Pathology in the AMA
S3Ep7: Everything You Need to Know About RISE
Special Episode: Castleman's Disease
S3Ep6:Leadership Institute Book Club: Invisible Women by Caroline Criado Perez
S3Ep5: Sometimes It’s a Zebra: Unusual Cases in Surgical Pathology—with Dr. Cesar Moran
S3Ep4: Leading Laboratories
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.